Richard Steinhart
Director of Finance/CFO chez BIOXCEL THERAPEUTICS, INC.
Fortune : 15 912 $ au 31/03/2024
Profil
Richard I.
Steinhart is currently an Independent Director at Atossa Therapeutics, Inc., Actinium Pharmaceuticals, Inc., and Chief Financial & Accounting Officer, Senior VP at BioXcel Therapeutics, Inc. He was previously an Independent Director at TG Therapeutics, Inc., Managing Director at Forest Street Capital, LLC, Managing Director at SAE Ventures, CFO & Vice President at Emisphere Technologies, Inc., CFO, Secretary, Treasurer & Senior VP-Finance at STRATA Skin Sciences, Inc., CFO & General Partner at CW Group, Inc., CFO & Vice President at Remedy Pharmaceuticals, Inc., and CFO & SVP-Finance at MELA Sciences Inc. He received his undergraduate and MBA degrees from Pace University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 04/04/2024 | 4 765 ( 0,01% ) | 13 437 $ | 31/03/2024 | |
| 28/12/2023 | 316 ( 0,00% ) | 2 474 $ | 31/03/2024 | |
| 15/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Richard Steinhart
| Sociétés | Poste | Début |
|---|---|---|
| ACTINIUM PHARMACEUTICALS, INC. | Director/Board Member | 08/11/2013 |
| ATOSSA THERAPEUTICS, INC. | Director/Board Member | 03/03/2014 |
| BIOXCEL THERAPEUTICS, INC. | Director of Finance/CFO | 01/10/2017 |
Anciens postes connus de Richard Steinhart
| Sociétés | Poste | Fin |
|---|---|---|
Remedy Pharmaceuticals, Inc.
 Remedy Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Remedy Pharmaceuticals, Inc. develops and commercializes pharmaceutical ingridients. It focuses on small molecule drugs for acute central nervous system disorders. The company was founded by David M. Geliebter and Sven M. Jacobson in 2004 and is headquartered in New York, NY. | Director of Finance/CFO | 01/04/2017 |
| STRATA SKIN SCIENCES, INC. | Director of Finance/CFO | 31/12/2013 |
| TG THERAPEUTICS, INC. | Director/Board Member | 01/01/2012 |
| Forest Street Capital, LLC | Corporate Officer/Principal | 24/04/2006 |
| EMISPHERE TECHNOLOGIES, INC. | Director of Finance/CFO | 01/05/1992 |
Formation de Richard Steinhart
| Pace University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| TG THERAPEUTICS, INC. | Health Technology |
| STRATA SKIN SCIENCES, INC. | Health Technology |
| ATOSSA THERAPEUTICS, INC. | Health Technology |
| ACTINIUM PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Emisphere Technologies, Inc.
 Emisphere Technologies, Inc. Pharmaceuticals: MajorHealth Technology Emisphere Technologies, Inc. is a commercial stage specialty pharmaceutical company, which engages in the development of new formulations of existing products and chemical entities, using Eligen Technology. Its product pipelines include eligen B12, eligen12.com, eligen B12 information, and purchase eligen B12. The company was founded in 1986 and is headquartered in Roseland, NJ. | Health Technology |
CW Group, Inc.
 CW Group, Inc. Investment ManagersFinance CW Group Inc. (CW Group) is a venture capital firm founded in 1982. The firm is headquartered in New York. | Finance |
Remedy Pharmaceuticals, Inc.
Remedy Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Remedy Pharmaceuticals, Inc. develops and commercializes pharmaceutical ingridients. It focuses on small molecule drugs for acute central nervous system disorders. The company was founded by David M. Geliebter and Sven M. Jacobson in 2004 and is headquartered in New York, NY. | Health Technology |
| SAE Ventures | |
| BioXcel Therapeutics, Inc. | |
| MELA Sciences Inc. | |
| Forest Street Capital, LLC |
